Matthias Frick
Overview
Explore the profile of Matthias Frick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
641
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mink S, Saely C, Leiherer A, Reimann P, Frick M, Cadamuro J, et al.
JCI Insight
. 2024 Oct;
9(20).
PMID: 39435658
BACKGROUNDDespite the currently prevailing, milder Omicron variant of COVID-19, older adults remain at elevated risk of hospital admission, critical illness, and death. Loss of efficacy of the immune system, including...
2.
Zweiker D, Koppelstatter C, Hohenstein K, Lang I, Perl S, Bugger H, et al.
Wien Klin Wochenschr
. 2024 Sep;
136(Suppl 14):559-569.
PMID: 39311980
Renal sympathetic denervation (RDN) is an interventional supplement to medical treatment in patients with arterial hypertension. While the first sham-controlled trial, SYMPLICITY HTN‑3 was neutral, with improved procedural details, patient...
3.
Mink S, Drexel H, Leiherer A, Cadamuro J, Hitzl W, Frick M, et al.
Vaccines (Basel)
. 2024 Aug;
12(8).
PMID: 39203980
Objectives: Despite the currently prevailing, milder Omicron variant, coronary artery disease (CAD) patients constitute a major risk group in COVID-19, exhibiting 2.6 times the mortality risk of non-CAD patients and...
4.
Brandt M, Alber H, Berger R, Binder R, Mascherbauer J, Niessner A, et al.
Wien Klin Wochenschr
. 2024 May;
136(Suppl 3):61-74.
PMID: 38743084
Introduction: Percutaneous coronary intervention is a well-established revascularization strategy for patients with coronary artery disease. Recent technical advances such as radial access, third generation drug-eluting stents and highly effective antiplatelet...
5.
Brandt M, Alber H, Berger R, Binder R, Mascherbauer J, Niessner A, et al.
Wien Klin Wochenschr
. 2024 May;
136(Suppl 3):44-60.
PMID: 38743083
Introduction: Percutaneous coronary intervention is a well-established revascularization strategy for patients with coronary artery disease. The safety and feasibility of performing these procedures on a same-day discharge basis for selected...
6.
Brandt M, Niessner A, Frick M
Wien Klin Wochenschr
. 2024 May;
136(Suppl 3):43.
PMID: 38743082
No abstract available.
7.
Mink S, Drexel H, Leiherer A, Frick M, Reimann P, Saely C, et al.
Int J Infect Dis
. 2024 Mar;
143:107016.
PMID: 38521446
Objectives: Despite high global vaccination coverage, it remains unclear how vaccination and anti-SARS-CoV-2 antibodies affect immune responses and inflammation levels in patients with COVID-19. It is further unclear whether the...
8.
Mink S, Saely C, Leiherer A, Frick M, Plattner T, Drexel H, et al.
Sci Rep
. 2023 Oct;
13(1):18326.
PMID: 37884649
Patients with type 2 diabetes (T2D) constitute one of the most vulnerable subgroups in COVID-19. Despite high vaccination rates, a correlate of protection to advise vaccination strategies for novel SARS-CoV-2...
9.
Mink S, Saely C, Frick M, Leiherer A, Drexel H, Fraunberger P
J Clin Med
. 2023 Aug;
12(15).
PMID: 37568470
Background: Recent studies suggest that both lipid levels and anti-severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2) antibody levels are associated with outcome in coronavirus disease 2019 (COVID-19). While both parameters have separately been implicated in...
10.
Mink S, List W, Hoefle G, Frick M, Suessenbacher A, Winder T, et al.
J Intern Med
. 2023 Jan;
293(6):694-703.
PMID: 36682036
Background: Millions of people have now been vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, it is still unclear which antibody levels provide protection against mortality. It is...